Australia markets open in 8 hours 35 minutes

Vivoryon Therapeutics N.V. (VVY.AS)

Amsterdam - Amsterdam Delayed price. Currency in EUR
Add to watchlist
0.7660-0.0290 (-3.64%)
As of 05:09PM CEST. Market open.
Currency in EUR

Valuation measures4

Market cap (intra-day) 20.72M
Enterprise value -7.82M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)26.60
Price/book (mrq)0.79
Enterprise value/revenue 28.97
Enterprise value/EBITDA -24.26

Trading information

Stock price history

Beta (5Y monthly) 1.23
52-week change 3-95.24%
S&P500 52-week change 326.27%
52-week high 317.2000
52-week low 30.4100
50-day moving average 30.9255
200-day moving average 37.3199

Share statistics

Avg vol (3-month) 3825.68k
Avg vol (10-day) 3604.9k
Shares outstanding 526.07M
Implied shares outstanding 626.56M
Float 820.18M
% held by insiders 125.56%
% held by institutions 135.70%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)484.67%

Management effectiveness

Return on assets (ttm)-56.74%
Return on equity (ttm)-107.38%

Income statement

Revenue (ttm)-3.62M
Revenue per share (ttm)-0.14
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -28.07M
Net income avi to common (ttm)-28.34M
Diluted EPS (ttm)-1.1200
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)28.73M
Total cash per share (mrq)1.16
Total debt (mrq)38k
Total debt/equity (mrq)0.14%
Current ratio (mrq)9.37
Book value per share (mrq)1.07

Cash flow statement

Operating cash flow (ttm)-21.54M
Levered free cash flow (ttm)-11.32M